CN116832085A - Traditional Chinese medicine composition for improving clinical symptoms of chronic renal failure patient - Google Patents

Traditional Chinese medicine composition for improving clinical symptoms of chronic renal failure patient Download PDF

Info

Publication number
CN116832085A
CN116832085A CN202310422228.9A CN202310422228A CN116832085A CN 116832085 A CN116832085 A CN 116832085A CN 202310422228 A CN202310422228 A CN 202310422228A CN 116832085 A CN116832085 A CN 116832085A
Authority
CN
China
Prior art keywords
parts
traditional chinese
chinese medicine
medicine composition
root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310422228.9A
Other languages
Chinese (zh)
Inventor
胡静
郭玥
刘文瑞
段连香
杨国彬
刘子洋
陈文浩
路建饶
陈杰
廖琳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Seventh Peoples Hospital
Original Assignee
Shanghai Seventh Peoples Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Seventh Peoples Hospital filed Critical Shanghai Seventh Peoples Hospital
Priority to CN202310422228.9A priority Critical patent/CN116832085A/en
Publication of CN116832085A publication Critical patent/CN116832085A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486—Millettia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/716—Clematis (leather flower)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The application provides a traditional Chinese medicine external composition for improving clinical symptoms of chronic renal failure patients. Specifically, the application provides a traditional Chinese medicine composition composed of prepared aconite, garden balsam stem, suberect spatholobus stem, clematis root, cassia twig and achyranthes root. The traditional Chinese medicine composition has the advantages of simple formula, efficacy of activating blood and dissolving stasis, definite clinical curative effect when being combined with oral administration of traditional Chinese medicines, and application prospect in the field of chronic renal failure treatment.

Description

Traditional Chinese medicine composition for improving clinical symptoms of chronic renal failure patient
Technical Field
The application relates to the field of traditional Chinese medicine treatment, in particular to a traditional Chinese medicine composition for improving clinical symptoms of patients with chronic renal failure.
Background
Chronic renal failure (Chronic Renal Failure, CRF) is a chronic kidney parenchymal injury caused on the basis of various primary or secondary kidney diseases. With the development of the disease course, when the kidney parenchyma is mostly damaged, the kidney can not maintain the basic functions, and complications such as metabolic disorder, water, electrolyte, acid-base imbalance and the like are clinically occurred. CRF incidence tends to increase year by year, medical expenses are high, social regression rate of patients is low, and heavy burden is brought to families and society of patients.
CRF has no effective radical cure medicine at present. Western medicine treatment comprises treating primary disease, nourishing, improving kidney microcirculation, and treating complications by oral intestinal adsorbent. According to the revised common understanding of protein nutrition treatment for chronic kidney disease in 2005, low protein diets are recommended to be matched with alpha-keto acid preparation for treatment. However, α -keto acid formulations are expensive, so searching for a better solution to treat CRF is a focus of clinical medicine today.
At present, traditional Chinese medicine shows considerable advantages in the aspect of treating CRF, and a large number of clinical researches prove that the traditional Chinese medicine can relieve or eliminate symptoms, improve general conditions, delay the course of disease, and possible mechanisms of the traditional Chinese medicine are the alleviation of glomerulosclerosis, renal interstitial fibrosis and the like. However, at present, the CRF traditional Chinese medicine treatment mainly adopts an oral prescription, and the treatment means is single.
Therefore, there is a need in the art to develop new therapeutic approaches and drugs for CRF traditional Chinese medicine.
Disclosure of Invention
The application aims to provide a traditional Chinese medicine composition for improving clinical symptoms of patients with chronic renal failure.
In a first aspect of the present application, there is provided a Chinese medicinal composition comprising the following raw materials or extracts thereof:
10-20 parts of cooked aconite root;
10-20 parts of garden balsam stem;
10-20 parts of spatholobus stem;
10-20 parts of radix clematidis;
10-20 parts of cassia twig;
10-20 parts of achyranthes root.
In another preferred embodiment, the crude drug comprises a fresh drug, a partially dried drug, a dried drug, or a combination thereof.
In another preferred embodiment, the extraction comprises water extraction, alcohol extraction, or a combination thereof.
In another preferred example, when the composition comprises the raw medicinal materials, parts by weight thereof are calculated based on dry weight of the respective raw medicinal materials.
In another preferred embodiment, the traditional Chinese medicine composition contains the following raw materials or extracts thereof:
12-18 parts by weight of cooked aconite, preferably 14-16 parts by weight, more preferably 15 parts by weight;
12-18 parts by weight of garden balsam stem, preferably 14-16 parts by weight, more preferably 15 parts by weight;
12-18 parts by weight of spatholobus stem, preferably 14-16 parts by weight, more preferably 15 parts by weight;
12-18 parts by weight of radix clematidis, preferably 14-16 parts by weight, more preferably 15 parts by weight;
12-18 parts by weight of cassia twig, preferably 14-16 parts by weight, more preferably 15 parts by weight;
12-18 parts by weight of achyranthes root, preferably 14-16 parts by weight, more preferably 15 parts by weight.
In another preferred example, in the traditional Chinese medicine composition, the weight ratio of the prepared aconite, the garden balsam stem, the suberect spatholobus stem, the clematis root, the cassia twig and the achyranthes root is (0.7-1.3): (0.7-1.3): (0.7-1.3): (0.7-1.3): (0.7-1.3): (0.7-1.3), preferably 1:1:1:1:1:1.
in another preferred embodiment, the Chinese medicinal composition consists of:
10-20 g, preferably 12-18 g, more preferably 15g of cooked aconite;
10-20 g, preferably 12-18 g, more preferably 15g of garden balsam stem;
10-20 g of suberect spatholobus stem, preferably 12-18 g, more preferably 15 g;
10-20 g of radix clematidis, preferably 12-18 g, more preferably 15 g;
10-20 g, preferably 12-18 g, more preferably 15g of cassia twig;
10-20 g of radix achyranthis bidentatae, preferably 12-18 g, more preferably 15g.
In another preferred embodiment, the Chinese medicinal composition comprises radix Aconiti lateralis Preparata 15g, herba speranskiae tuberculatae 15g, caulis Spatholobi 15g, radix Clematidis 15g, ramulus Cinnamomi 15g, and radix Achyranthis bidentatae 15g.
In a second aspect of the present application, there is provided a pharmaceutical formulation for external use, the formulation comprising:
i) The traditional Chinese medicine composition according to the first aspect of the application;
ii) other pharmaceutically acceptable excipients, or carriers.
In another preferred embodiment, the pharmaceutical formulation is a traditional Chinese medicine formulation.
In another preferred embodiment, the formulation is selected from the group consisting of: powder, ointment, dry powder, topical pack, or a combination thereof.
In another preferred embodiment, the pharmaceutically acceptable excipients include fillers, excipients, antiallergic agents, exothermic agents, or combinations thereof.
In a third aspect of the present application, there is provided the use of a Chinese medicinal composition according to the first aspect of the present application or a topical pharmaceutical formulation according to the second aspect of the present application for the manufacture of a topical medicament for the prevention and/or treatment of chronic renal failure.
In another preferred embodiment, the chronic renal failure is characterized by a symptom selected from the group consisting of: lumbago, aversion to cold, proteinuria, edema, hypertension, urine retention or a combination thereof.
In another preferred embodiment, the preventing and/or treating chronic renal failure comprises:
a) Lowering serum creatinine, or urea nitrogen, or uric acid, or a combination thereof; and/or
b) The eGFR is improved.
In a fourth aspect of the application, there is provided a method of ameliorating clinical symptoms in a patient suffering from chronic renal failure comprising the steps of: administering to a subject in need thereof a therapeutically effective amount of a traditional Chinese medicine composition according to the first aspect of the application or a pharmaceutical formulation according to the second aspect of the application.
In another preferred embodiment, the subject is a chronic renal failure patient.
In a fifth aspect of the application, there is provided a kit comprising:
a) The traditional Chinese medicine composition according to the first aspect of the application, the external pharmaceutical preparation according to the second aspect of the application, or a combination thereof;
b) The second traditional Chinese medicine composition or a preparation containing the same comprises the following raw materials or extracts of the raw materials: 10-20 parts of raw astragalus, 10-20 parts of red sage root, 6-15 parts of peach kernel, 6-15 parts of herba lycopi, 10-20 parts of glossy privet fruit, 10-20 parts of eclipta alba, 20-40 parts of cogongrass rhizome, 20-40 parts of rheum officinale and 10-20 parts of winged euonymus twig.
In another preferred embodiment, the second traditional Chinese medicine composition is composed of the following raw materials or extracts thereof: 15 parts of raw astragalus root, 15 parts of red sage root, 10 parts of peach kernel, 10 parts of herba lycopi leaf, 15 parts of glossy privet fruit, 15 parts of eclipta alba, 30 parts of cogongrass rhizome, 30 parts of rheum officinale, and 15 parts of winged euonymus twig.
In another preferred embodiment, the second traditional Chinese medicine composition is composed of the following raw materials or extracts thereof: 15g of raw astragalus root, 15g of red sage root, 10g of peach kernel, 10g of herba lycopi leaf, 15g of glossy privet fruit, 15g of eclipta alba, 30g of cogongrass rhizome, 30g of rheum officinale and 15g of winged euonymus twig.
In another preferred embodiment, the extract is an aqueous extract, an alcoholic extract, or a combination thereof.
In another preferred embodiment, the formulation is an oral formulation.
It is understood that within the scope of the present application, the above-described technical features of the present application and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.
Detailed Description
The inventor of the present application has developed a Chinese medicinal composition for improving clinical symptoms of chronic renal failure patients for the first time through extensive and intensive studies. The application uses the guiding thought of 'promoting blood circulation by removing blood stasis throughout treatment' as the treatment of chronic kidney disease, and uses prepared aconite root to tonify fire, strengthen yang, dispel cold and relieve pain; herba speranskiae tuberculatae, radix Clematidis, dampness eliminating and vein relaxing; caulis Spatholobi has effects of promoting blood circulation and dredging collaterals; ramulus Cinnamomi warms and unblocks blood vessels, radix Achyranthis bidentatae tonifies liver and kidney, activates blood circulation and relieves pain. The prescription is simple, and the external treatment method by ironing takes effect, thereby not only playing the role of warming yang and dredging collaterals, but also avoiding the oral toxicity of medicines such as prepared aconite, and the like, and improving the safety of the preparation. The composition has definite clinical application curative effect, and can obviously improve clinical symptoms of chronic renal failure patients such as aversion to cold, cold limbs, soreness and weakness of waist and knees, frequent nocturia, edema and the like. On this basis, the present application has been completed.
Terminology
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
As used herein, the terms "comprising," "including," and "containing" are used interchangeably, and include not only closed-form definitions, but also semi-closed-form and open-form definitions. In other words, the term includes "consisting of … …", "consisting essentially of … …".
As used herein, the term "pharmaceutically acceptable adjuvant, carrier or vehicle" component refers to a substance that is suitable for use in humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response), commensurate with a reasonable benefit/risk ratio.
As used herein, the term "effective amount" refers to an amount that is functional or active in and acceptable to a human and/or animal. It will be appreciated by those of ordinary skill in the art that the "effective amount" may vary depending on the form of the pharmaceutical composition, the severity of the disease, and the combination with other drugs.
The terms "preventing", "treating" or "ameliorating" as used herein include delaying and stopping the progression of the disease, or eliminating the disease, and do not require 100% inhibition, elimination and reversal. In some embodiments, the inventive traditional Chinese medicine composition or pharmaceutical formulation is capable of preventing the production of chronic glomerulonephritis, or reducing, inhibiting and/or reversing an existing chronic glomerulonephritis or symptoms caused thereby, for example, by at least about 10%, at least about 30%, at least about 50%, or at least about 80% as compared to the levels observed in the absence of the inventive traditional Chinese medicine composition or pharmaceutical formulation.
As used herein, the terms "parts by weight" and "parts by weight" are used interchangeably and the parts by weight may be any fixed weight in milligrams, grams, or kilograms (e.g., 1mg, 1g, 2g, or 1kg, etc.). For example, a composition comprising 1 part by weight of component a and 9 parts by weight of component b may be a composition comprising 1 gram of component a+9 gram of component b, or 10 grams of component a+90 gram of component b, etc. In the composition, the percentage content of a certain component= (the parts by weight of the component/the sum of the parts by weight of all components) ×100%, and therefore, in the composition composed of 1 part by weight of component a and 9 parts by weight of component b, the content of component a is 10%, and the content of component b is 90%.
As used herein, the term "raw medicinal material" refers to a traditional Chinese medicinal material that is an active medicinal material in the composition of the present application, and the medicinal material may include various forms, for example, the medicinal material includes (but is not limited to) dry medicinal material, fresh medicinal material, raw medicinal material, cooked medicinal material, processed medicinal material, or a combination thereof. In addition, when the composition of the present application contains a certain crude drug extract, the term also includes the crude drug corresponding to the crude drug extract or the corresponding crude drug used for preparing the extract.
The traditional Chinese medicine composition of the application
The application provides a traditional Chinese medicine composition for preventing, treating and/or improving chronic renal failure.
Study theory support: the traditional Chinese medicine considers that the basic pathogenesis of chronic renal failure is congenital deficiency or acquired failure in regulation and control, which causes spleen and kidney functions to be damaged, triple energizer to be unfavorable, water dampness to be stopped internally, and turbid pathogen to be dissolved for a long time to cause water dampness to be drowned, toxin to be stopped in triple energizer, which is the syndrome of deficiency and excess, namely "the chronic disease is necessary to be stasis", so that the blood circulation is activated and the stasis is removed throughout the treatment of chronic kidney disease. The early stage of chronic renal failure is mainly characterized by proteinuria, hematuria and the like, and the later stage is mainly characterized by edema. Aversion to cold, cold limbs, soreness and weakness of waist and knees, frequent nocturia, and frequent nocturia are common clinical manifestations of chronic renal failure. The application combines the prepared aconite, the garden balsam stem, the clematis root, the suberect spatholobus stem, the cassia twig, the achyranthes root and the six medicines, and the mixture is ground into powder and sewn into bags, and the hot ironing patient has double kidney Shu points, three jiao Shu points and Pishu points. By external treatment with ironing, the clinical symptoms of patients with chronic renal failure can be unexpectedly improved.
And (3) square solution: she Shi the ironing prescription comprises radix Aconiti lateralis Preparata, herba speranskiae tuberculatae, radix Clematidis, caulis Spatholobi, ramulus Cinnamomi, and radix Achyranthis bidentatae. The prepared aconite root tablet has the functions of tonifying fire, supporting yang, dispelling cold and relieving pain; herba speranskiae tuberculatae, radix Clematidis, dampness eliminating and vein relaxing; caulis Spatholobi has effects of promoting blood circulation and dredging collaterals; ramulus Cinnamomi warms and unblocks blood vessels, radix Achyranthis bidentatae tonifies liver and kidney, activates blood circulation and relieves pain. The whole formula has the functions of dispelling wind and eliminating dampness, dispelling cold and relieving pain, and activating blood and dredging collaterals. The recipe is suitable for chronic renal failure with stagnation of qi and blood stasis and turbid toxin.
The radix Aconiti lateralis Preparata is the root of Aconitum carmichaeli Aconitum carmichaelii Debeaux belonging to Ranunculaceae. Pungent and sweet in flavor, and big in heat. Is toxic. It enters heart, kidney and spleen meridians. Has effects of restoring yang, rescuing collapse, nourishing fire, supporting yang, dispelling cold and relieving pain.
Herba speranskiae tuberculatae is whole herb of the genus Euphorbiaceae, the genus Euphorbia, euphorbia Speranskia tuberculata (Bunge) baill. Sweet and pungent in flavor and warm in nature. It enters lung and liver meridians. Has effects of dispelling pathogenic wind, removing dampness, relieving rigidity of muscles, activating collaterals, promoting blood circulation, relieving pain, removing toxic substance, and removing eruption.
Caulis Spatholobi is dried rattan of Spatholobus suberectus Dunn Spatholobus suberectus Dunn of Leguminosae. Bitter and sweet in flavor and warm in nature. It enters liver and kidney meridians. Has effects of promoting blood circulation, replenishing blood, regulating menstruation, relieving pain, relaxing muscles and tendons, and activating collaterals.
Radix Clematidis is dried root and rhizome of radix Clematidis Clematis chinensis Osbeck, herba Clematidis Clematis hexapetala pall. Or herba Clematidis Clematis manshurica rupr. Of Ranunculaceae. Pungent and salty in flavor and warm in nature. Enter bladder meridian. Has effects in dispelling pathogenic wind and dampness, and dredging channels and collaterals.
Ramulus Cinnamomi is dried twig of Cinnamomum cassia Cinnamomum cassia Presl belonging to Lauraceae. Pungent and sweet in flavor and warm in nature. It enters heart, lung and bladder meridians. Has effects in inducing sweat, relieving exterior syndrome, dispelling cold, relieving pain, activating yang, and activating qi-flowing.
The radix Achyranthis bidentatae is dry root of radix Achyranthis bidentatae Achyranthes bidentata Bl. belonging to Amaranthaceae. Bitter, sweet, sour and neutral in flavor. It enters liver and kidney meridians. Has effects of removing blood stasis, dredging channels, nourishing liver and kidney, strengthening tendons and bones, inducing diuresis, treating stranguria, and promoting blood circulation.
Formulations and administration
The application provides a preparation, which contains one or more medicinal materials or extracts thereof of prepared aconite, garden balsam stem, clematis root, suberect spatholobus stem, cassia twig and achyranthes root. In the preparation, the content of the raw medicinal materials or the extracts thereof can be 0.1-99.9wt% based on the weight of the preparation. The composition may also contain a pharmaceutically or nutraceutically acceptable carrier. Preferably, the formulation of the present application is prepared as follows:
the following components in parts by weight are mixed to obtain the composition of the application:
10-20 parts by weight of cooked aconite;
10-20 parts of garden balsam stem;
10-20 parts by weight of spatholobus stem;
10-20 parts by weight of radix clematidis;
10-20 parts by weight of cassia twig;
10-20 parts of achyranthes root.
In the present application, it should be understood that the extract not only contains the active ingredients (such as powder) obtained by extraction after mixing the raw materials, but also contains the active ingredients obtained by mixing the active ingredients obtained by extraction of the single raw materials (including the mixture between the concentrated solutions, the mixture between the active ingredients, or the mixture between the concentrated solution and the active ingredients). The active ingredients of the raw medicinal materials comprise single components or mixed components.
For the formulations of the present application, the preferred dosage form is a powder formulation. The preferred mode of administration is topical.
Various conventional carriers and/or auxiliary materials required for preparing different dosage forms can be added into the preparation. Pharmaceutically acceptable excipients useful in the present application include fillers, excipients, antiallergic agents, exothermic agents, or combinations thereof. In a preferred embodiment, the preparation is prepared into powder by a conventional method of traditional Chinese medicine preparation.
The preparation of the application is easy to preserve, and can conveniently and effectively meet the demands of patients.
The preparation of the application can be directly used for preparing external medicines for preventing and/or treating chronic renal failure. The formulations of the present application may also contain other drugs from other optional medicinal materials or extracts thereof or other drugs effective for the treatment and/or prevention of chronic glomerulonephritis. Preferably, the preparation of the present application can alleviate symptoms such as aversion to cold, cold limbs, soreness of waist and knees, frequent nocturia, etc. caused by chronic renal failure.
The formulations of the application are generally administered at a dosage of 0.001-20g/kg of animal body weight per day, preferably at 1-4 divided doses per day, or in a slow release form. For most mammals, the total daily dose is 0.05-600g. Of course, the particular dosage will vary with the mode of administration, the dosage form and the severity of the condition being treated, and these are within the skill of the skilled practitioner. Administration may be by conventional routes including, but not limited to: oral, intramuscular, dermal, or topical administration. Preferably, the administration is topical.
The present application also provides a method for preventing and/or treating chronic renal failure, the method comprising the steps of: the compositions or formulations of the present application are administered to a subject in need thereof. The subject may be a human or non-human mammal (e.g., dog, pig, cat, monkey, sheep, horse, cow, etc.).
The main advantages of the application include:
1) The traditional Chinese medicine composition has definite curative effect and high safety;
2) The preparation method of the traditional Chinese medicine composition is simple, low in cost and easy to obtain raw materials;
3) The traditional Chinese medicine composition disclosed by the application can be used for remarkably improving renal function, reducing serum creatinine and improving glomerular filtration rate.
The application will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present application and are not intended to limit the scope of the present application. The experimental procedure, which does not address the specific conditions in the examples below, is generally followed by routine conditions, such as, for example, sambrook et al, molecular cloning: conditions described in the laboratory Manual (New York: cold Spring Harbor Laboratory Press, 1989) or as recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.
The quality of the traditional Chinese medicine materials related by the application accords with the relevant regulations under a corresponding medicinal material item of 2010 edition of Chinese pharmacopoeia.
EXAMPLE 1 clinical Studies
1. Prescription, decoction method and prescription solution
She Shi ironing formula: 15g of cooked aconite, 15g of garden balsam stem, 15g of suberect spatholobus stem, 15g of clematis root, 15g of cassia twig and 15g of achyranthes root.
The using method comprises the following steps: pulverizing, sewing into bag, ironing to obtain Shenshu acupoint, sanjiaoshu acupoint and Pishu acupoint on both sides of patient. Twice daily for 10 minutes each time, and 2 months is 1 course of treatment.
And (3) square solution: she Shi the ironing prescription comprises radix Aconiti lateralis Preparata, herba speranskiae tuberculatae, radix Clematidis, caulis Spatholobi, ramulus Cinnamomi, and radix Achyranthis bidentatae. The prepared aconite root tablet is used as a monarch for tonifying fire, supporting yang, dispelling cold and relieving pain; the cassia twig is used for warming and activating blood vessels, the radix achyranthis bidentatae is used for tonifying liver and kidney, activating blood and relieving pain; the garden balsam stem and the clematis root are assisted to dispel dampness and remove meridian obstruction, and the suberect spatholobus stem is used for promoting blood circulation and removing meridian obstruction. The whole formula has the functions of dispelling wind and eliminating dampness, dispelling cold and relieving pain, and activating blood and dredging collaterals.
2. Results of the study
The study incorporates CKD2-4 patients meeting the diagnostic and staging criteria of the kidney disease quality of life guidelines (K/DOQI) established by the U.S. kidney disease foundation; meets the diagnostic standard of traditional Chinese medicine; stable condition between 18-80 years of age. Excluding those suffering from acute renal failure or acute exacerbation of chronic renal insufficiency; life threatening patients with severe hyperkalemia, heart failure, uremic encephalopathy, etc.; is combined with serious primary diseases of cardiovascular, liver and hematopoietic systems. The cases are from patients who follow-up with chronic nephrosis outpatient and nephrology specialist outpatient in seventh people hospital attached to Shanghai traditional Chinese medicine university.
The test group is combined with She Shi ironing prescription consisting of wind-dispelling dampness-eliminating, cold-dispelling pain-relieving, blood-activating and collaterals-dredging, and oral administration of the prescription for strengthening the body resistance and dredging collaterals (15 g of raw astragalus, 15g of radix salviae miltiorrhizae, 10g of peach kernel, 10g of herba lycopi, 15g of glossy privet fruit, 15g of eclipta alba, 30g of rhizoma imperatae, 30g of radix rhaponticum carthamoides and 15g of winged euonymus twig) is used for treating 64 cases of chronic renal failure patients, compared with 48 cases of chronic renal failure patients of the control group with pure oral administration of the prescription for strengthening the body resistance and dredging collaterals. The treatment time was 2 months. The patient was observed for creatinine SCr and glomerular filtration rate eGFR before treatment, after 1 month of treatment, and after 2 months of treatment.
Results: 64 test groups, wherein 12 cases are effective, 33 cases are effective, 9 cases are stable, and 10 cases are ineffective. The effective rate is 84.4%; the control group comprises 48 cases, namely 8 cases with obvious effect, 19 cases with effective effect, 10 cases with stable effect, 11 cases with ineffective effect, the effective rate is 77.1%, and the two cases have obvious difference after the statistical treatment of P < 0.005. As shown in tables 1 and 2: the comparison between groups shows that SCr decreases and eGFR increases after 2 months of administration of the test group, and the difference is statistically significant (p < 0.05) compared with the control group. The intra-group comparison shows that SCr decreased before treatment and eGFR increased before treatment after 2 months of treatment in the test group, and the difference is statistically significant. After 2 months of treatment, SCr increased and eGFR decreased compared to before treatment, and the difference was statistically significant (p < 0.05).
The study shows that the external She Shi ironing prescription can obviously improve laboratory indexes and clinical symptoms of chronic renal failure patients and delay CRF process. In particular, the eGFR index of the formula for strengthening the body resistance and dredging collaterals is not improved after two months of treatment, and the eGFR index of the formula for ironing by adding She Shi is unexpectedly and significantly improved.
TABLE 1 comparison of SCr (umol/l) before and after treatment
TABLE 2 comparison of eGFR (ml/min) before and after treatment
All documents mentioned in this disclosure are incorporated by reference in this disclosure as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the application as defined in the appended claims.

Claims (10)

1. The traditional Chinese medicine composition is characterized by comprising the following raw materials or extracts thereof:
10-20 parts of cooked aconite root;
10-20 parts of garden balsam stem;
10-20 parts of spatholobus stem;
10-20 parts of radix clematidis;
10-20 parts of cassia twig;
10-20 parts of achyranthes root.
2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition contains the following raw materials or extracts thereof:
14-16 parts of cooked aconite root;
14-16 parts of garden balsam stem;
14-16 parts of spatholobus stem;
14-16 parts of radix clematidis;
14-16 parts of cassia twig;
14-16 parts of achyranthes root.
3. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is composed of 15g of prepared aconite, 15g of garden balsam stem, 15g of suberect spatholobus stem, 15g of clematis root, 15g of cassia twig and 15g of achyranthes root.
4. A pharmaceutical formulation for external use, the formulation comprising:
i) The traditional Chinese medicine composition according to claim 1;
ii) other pharmaceutically acceptable excipients, or carriers.
5. The pharmaceutical formulation for external use according to claim 4, wherein the formulation is selected from the group consisting of: powder, ointment, dry powder, topical pack, or a combination thereof.
6. The pharmaceutical formulation for external use according to claim 4, wherein the pharmaceutically acceptable excipients comprise fillers, excipients, antiallergic agents, exothermic agents, or combinations thereof.
7. The use of the Chinese medicinal composition according to claim 1 or the external pharmaceutical preparation according to claim 4 for the preparation of an external medicament for the prevention and/or treatment of chronic renal failure.
8. The use according to claim 7, wherein said preventing and/or treating chronic renal failure comprises:
a) Lowering serum creatinine, or urea nitrogen, or uric acid, or a combination thereof; and/or
b) Improving glomerular filtration rate eGFR.
9. A kit, comprising:
a) The traditional Chinese medicine composition according to claim 1, the external pharmaceutical preparation according to claim 4, or a combination thereof;
b) The second traditional Chinese medicine composition or a preparation containing the same comprises the following raw materials or extracts of the raw materials: 10-20 parts of raw astragalus, 10-20 parts of red sage root, 6-15 parts of peach kernel, 6-15 parts of herba lycopi, 10-20 parts of glossy privet fruit, 10-20 parts of eclipta alba, 20-40 parts of cogongrass rhizome, 20-40 parts of rheum officinale and 10-20 parts of winged euonymus twig.
10. The kit of claim 9, wherein the formulation comprising the second traditional Chinese medicine composition is an oral formulation.
CN202310422228.9A 2023-04-19 2023-04-19 Traditional Chinese medicine composition for improving clinical symptoms of chronic renal failure patient Pending CN116832085A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310422228.9A CN116832085A (en) 2023-04-19 2023-04-19 Traditional Chinese medicine composition for improving clinical symptoms of chronic renal failure patient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310422228.9A CN116832085A (en) 2023-04-19 2023-04-19 Traditional Chinese medicine composition for improving clinical symptoms of chronic renal failure patient

Publications (1)

Publication Number Publication Date
CN116832085A true CN116832085A (en) 2023-10-03

Family

ID=88165937

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310422228.9A Pending CN116832085A (en) 2023-04-19 2023-04-19 Traditional Chinese medicine composition for improving clinical symptoms of chronic renal failure patient

Country Status (1)

Country Link
CN (1) CN116832085A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1724002A (en) * 2005-07-13 2006-01-25 马淑珍 Medicinal composition, and its pharmaceutical use
CN109820996A (en) * 2019-02-19 2019-05-31 贾世英 A kind of formulation for coating material for helping positive transdermal drug external application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1724002A (en) * 2005-07-13 2006-01-25 马淑珍 Medicinal composition, and its pharmaceutical use
CN109820996A (en) * 2019-02-19 2019-05-31 贾世英 A kind of formulation for coating material for helping positive transdermal drug external application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
郑平东, 周家俊, 高建东, 何立群: "固本通络冲剂治疗IgA肾病的临床疗效观察", 中国中西医结合肾病杂志, no. 03, 20 March 2003 (2003-03-20), pages 150 - 152 *
高建东: "固本通络冲剂对实验性IgA肾病肾组织6K-PGF_(1α)、TXB_2的调节作用", 中国中医药科技, vol. 10, no. 02, 30 March 2003 (2003-03-30), pages 63 - 64 *

Similar Documents

Publication Publication Date Title
KR20130058857A (en) Herbal composition for preventing and treating atopic dermatitis, and manufacturing method thereof
CN103386022A (en) Chinese medicine composition for treating tuberculous pleurisy
CN101143171B (en) Traditional Chinese medicine and its preparation method and its application
CN101987166B (en) Medicament for treating stye and preparation method thereof
CN110840978A (en) A Chinese medicinal composition for treating rheumatic arthritis and rheumatoid arthritis, and medicated liquor containing the same
CN116832085A (en) Traditional Chinese medicine composition for improving clinical symptoms of chronic renal failure patient
CN101987135B (en) Medicine for treating tetanus and preparation method thereof
CN111632110B (en) Traditional Chinese medicine enema composition for treating ulcerative colitis and preparation method and application thereof
CN1781538A (en) Chinese medicine preparation for treating mephritis and nephrosis syndrome
CN114028507A (en) Preparation method of traditional Chinese medicine for treating lumbago
CN111067941A (en) Traditional Chinese medicine suppository for treating chronic renal failure
CN105031595A (en) Traditional Chinese medicine tablet for treating nummular eczema and preparing method thereof
CN117224624B (en) Traditional Chinese medicine composition for preventing and/or treating renal edema and preparation method thereof
CN110585379A (en) External application medicine for treating dermatitis
CN116808145A (en) Traditional Chinese medicine composition for treating chronic kidney disease
CN113521206B (en) Traditional Chinese medicine composition containing burdock
CN107158131A (en) Treat Chinese medicine composition of dermatitis and preparation method thereof
CN102727791A (en) Medicine for treating AIDS and preparation method thereof
CN106309576A (en) Drug for treating haemorrhoids and preparation method thereof
CN104758346A (en) Medicine for treating migraine, as well as preparation method and preparation of medicine
CN101822767B (en) External plaster for treating sclerotin and osseous nerve diseases
CN112057587A (en) Traditional Chinese medicine composition for gout and preparation method, external medicine and application thereof
CN116850247A (en) Preparation method and composition of traditional Chinese medicine composition for treating hyperuricemia and gout
CN101322826B (en) Chinese medicine for treating cholecystitis and method of preparing the same
CN101703568B (en) Medicament for preventing and treating hepatitis B and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination